IDO1 and cancer: In this work, we show that this strategy can be applied with success in DCs derived from the THP-1 acute monocytic leukemia cell line as a model for the delivery of silencing strategies targeting the IDO1 gene that could enhance immunomodulation for cancer therapeutics.